Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Suvratoxumab (DXX00102)

Host species:Human
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DXX00102

Expression system

Mammalian Cells

Species reactivity

Staphylococcus aureus

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Alpha-hemolysin, hly, Alpha-HL, Alpha-toxin, hla

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P09616

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MEDI4893, CAS: 1629620-18-3

Clone ID

Suvratoxumab

Data Image
  • SDS-PAGE
    SDS PAGE for Suvratoxumab
  • Bioactivity
    Detects Alpha-toxin/hly in indirect ELISAs.
References

α-Toxin Induces Platelet Aggregation and Liver Injury during Staphylococcus aureus Sepsis, PMID: 30033122

Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity In Vitro and Staphylococcus aureus Fitness in Infection Models, PMID: 30150481

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial, PMID: 33894131

Development of a mechanism of action reflective and robust potency assay for a therapeutic antibody against alpha toxin using rabbit erythrocytes, PMID: 33075362

Staphylococcus aureus drives expansion of low-density neutrophils in diabetic mice, PMID: 30985291

Efficacy of a Multimechanistic Monoclonal Antibody Combination against Staphylococcus aureus Surgical Site Infections in Mice, PMID: 31138566

Mechanisms of neutralization of a human anti-α-toxin antibody, PMID: 25210036

Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment, PMID: 31341107

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model, PMID: 25987629

Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach, PMID: 28584141

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults, PMID: 27795368

Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model, PMID: 25348518

Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections, PMID: 27401576

Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893, PMID: 27324766

Datasheet

Document Download

Research Grade Suvratoxumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Suvratoxumab [DXX00102]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only